抗体药物时代的来临

The Age of Antibody-based Drugs is Coming——Current Status and Prospects

抗体作为免疫应答反应的主要产物,构筑了机体抵御感染和疾病的一道重要防线。早在一个多世纪之前,研究者就己开始探索将抗体作为药物治疗疾病。二十世纪七十年代中期,单克隆抗体制备技术的产生和基因工程技术的发展使抗体作为药物成为可能。单克隆抗体因具有特异性、多样性井且能够“量身定做”的特点而被寄予厚望,曾一度被称为疾病治疗的“魔弹”。生物技术制药企业也开始看好抗体药物的商业价值。二十世纪九十年代后期,抗体药物在经历了一段曲折的发展历程之后,又重新焕发出生机和活力。抗体药物的研究和开发迅速成为新世纪生物技术制药领域的一个重要发展方向,抗体药物治疗疾病的时代已经来临。

As an effector agent in the first line of the body's defense systems against foreign invaders, antibodies have been investigated as therapeutics for more than a century. Since the 1970s, the application of hybridoma technology and genetic engineering technology in making monoclonal antibody and engineered antibody has greatly promoted the development of antibody-based drugs for treatment of various diseases, especially cancers. Particularly in recent 5 years, with the approval of several monoclonal antibodies and conjugates for clinical use, antibody-based drugs as important part of biotechnology medicines have shown great therapeutic potential. Evidently, the age of antibody-based drugs is approaching.